Bluebird bio Inc

NASDAQ:BLUE  
9.97
-0.66 (-6.21%)
Products

Bluebird Bio Announces FDA Priority Review Of Biologics License Application For Beti-Cel Gene Therapy

Published: 11/22/2021 11:36 GMT
Bluebird bio Inc (BLUE) - Bluebird Bio Announces FDA Priority Review of Biologics License Application for Beti-cel Gene Therapy for Patients With Β-thalassemia Who Require Regular Red Blood Cell Transfusions.
Bluebird Bio Inc - FDA Set PDUFA Date of May 20, 2022.